Acutaas Chemicals

    ACUTAAS
    Pharma
    ₹3,991.30
    Price as of 18 Nov 2026, 9:58 pm IST

    Market cap ₹32,677 Cr

    P/E
    74.72
    Day range
    ₹3,934.20 – ₹4,017.60
    52-week range
    ₹1,570.00 – ₹4,130.00
    Volume
    2.44 L
    Open
    ₹3,935.00
    Prev close
    ₹3,942.90

    Latest results · Q2 FY27(consolidated)Revenue ₹437 Cr+42.7%Profit ₹123 Cr+71.4%Margin 28.2%YoY vs the same quarter last year

    No red flags in exchange filings: no rising pledge, promoter selling, surveillance or critical filing on record.

    Research profile

    Composite 64 / 100

    Factor percentiles

    Value18
    Quality82
    Momentum94
    Low volatility64

    Derived metrics

    Earn. yield
    1.3%
    Graham no.
    ₹520.31
    vs Graham
    -87.0%
    ROE ÷ P/B
    1.4%
    12-1 mom.
    +81.7%
    Return / vol
    2.78
    Magic Formula
    #309
    Piotroski
    4/6
    FCF yield
    -0.1%

    Percentiles rank this stock against the other tracked stocks and change as they do. Scans describe where figures sit today. Hover a label for its definition. Not investment advice.

    Peer comparison

    All 68 in Pharma
    Largest Pharma companies tracked, with sector medians
    CompanyM-capP/EP/BROEROCEOPMD/ESales YoY
    Sun PharmaSUNPHARMA₹4.49 L Cr40.955.0314.8%21.0%29.0%0.04+11.9%
    Divi's LaboratoriesDIVISLAB₹2.93 L Cr87.1916.8816.2%22.0%43.0%0.00+35.4%
    Torrent PharmaTORNTPHARM₹1.75 L Cr77.889.6726.8%15.0%33.0%0.77+50.8%
    Apollo HospitalsAPOLLOHOSP₹1.27 L Cr56.4011.5522.6%17.0%16.0%0.77+23.0%
    Laurus LabsLAURUSLABS₹1.25 L Cr93.7219.8218.2%18.0%34.0%0.43+33.5%
    Zydus LifesciencesZYDUSLIFE₹1.20 L Cr28.724.3220.1%21.0%24.0%0.50+29.2%
    Dr. Reddy's LabsDRREDDY₹1.17 L Cr41.632.9711.6%13.0%20.0%0.19-1.5%
    Acutaas ChemicalsACUTAAS₹32,677 Cr74.7217.7924.0%32.0%40.0%0.01+42.8%
    Sector median₹24,603 Cr43.685.4615.1%17.0%24.0%0.17+22.7%

    Sector as classified in the tracked universe; medians use every tracked Pharma company, and P/E only profitable ones. Tinted figures beat the median.

    Latest news

    Updated 6h ago

    Headlines about Acutaas Chemicals from the last two weeks in the financial press. Stories belong to their publishers; Rajat Finance does not endorse them.

    Key metrics

    P/E (TTM)
    74.4
    EPS (TTM)
    ₹47.06
    Price / Book
    17.58
    ROE (FY26)
    24.0%
    ROCE (latest year)
    32%
    Dividend yield
    0.06%

    Moving averages (NSE)

    20-day
    ₹3,759.26
    Price above
    50-day
    ₹3,447.19
    Price above
    200-day
    ₹2,951.97
    Price above

    Charts & trends

    From company filings. Amounts in ₹ crore.

    Revenue 3Y CAGR
    +29.5%
    Profit 3Y CAGR
    +62.5%
    Revenue YoY (Sep 2026)
    +42.8%
    Profit YoY (Sep 2026)
    +70.8%
    Operating margin
    40.0%
    Net margin
    28.1%

    Revenue, profit & margin - quarterly

    ₹ crore; a loss shows red. Operating margin below, same periods.

    0 Cr200 Cr400 Cr600 Cr
    • Revenue
    • Net profit

    Operating margin

    Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Sep 20260%25%50%

    Who owns the company

    % of equity by quarter, latest Sept 2026

    Dec '24Mar '25Jun '25Sept '25Dec '25Mar '26Jun '26Sept '260%25%50%75%100%
    • Promoter
    • Public
    • FII
    • DII
    • Government

    Cash flows

    Where cash came from and went, by fiscal year (₹ crore)

    Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026-400 Cr-200 Cr0 Cr200 Cr400 Cr
    • Operating
    • Investing
    • Financing
    • Free cash flow

    Return on equity

    Net profit over shareholders' equity, by fiscal year

    FY18FY19FY20FY21FY22FY23FY24FY25FY260%10%20%30%40%15% screen

    Equity vs debt

    Shareholders' equity against borrowings (₹ crore); the ratio below, same years.

    0 Cr500 Cr1K Cr1.5K Cr2K Cr
    • Equity
    • Debt

    Debt to equity

    Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 20260x0.5x1x

    Dividends per share

    ₹ by fiscal year of the ex-date; the latest year runs to date. Not adjusted for the split of 25 Apr 2025: earlier bars are per pre-split share.

    FY24FY25FY26FY27₹0₹1₹2₹3

    Financial statements

    ₹ Crore
    Quarterly results, oldest period first, figures in rupees crore
    Line itemDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026
    Sales166225177247275308207306393433330437
    Expenses140182147198206224156211243249217261
    Operating Profit2743304969855195151184113176
    OPM %16%19%17%20%25%28%25%31%38%42%34%40%
    Other Income311826161051125
    Interest324011111111
    Depreciation4567678810101013
    Profit before tax2437205063835896145184104167
    Tax %25%31%26%25%28%24%24%25%27%27%28%26%
    Net Profit182615384563447210613475123
    EPS in Rs₹2.27₹3.41₹1.71₹4.56₹5.49₹7.63₹5.41₹8.82₹13.19₹16.09₹9.07₹15.29

    From company filings, updated 19 Nov 2026. Consolidated figures where the company reports them. Information only, not investment advice.

    Working-capital cycle

    Debtor Days99

    -30 days since Mar 2021

    Inventory Days149

    +26 days since Mar 2021

    Days Payable99

    -73 days since Mar 2021

    Cash Conversion Cycle149

    +69 days since Mar 2021

    Working Capital Days116

    +65 days since Mar 2021

    Strengths, risks & growth

    Ami Organics Limited is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals. [1]

    Strengths

    • Company is almost debt free.
    • Company is expected to give good quarter
    • Company has delivered good profit growth of 45.8% CAGR over last 5 years

    Risks

    • Stock is trading at 17.6 times its book value
    • Promoter holding has decreased over last 3 years: -6.27%

    Compounded Sales Growth

    10 Years
    —
    5 Years
    +32%
    3 Years
    +30%
    TTM
    +45%

    Compounded Profit Growth

    10 Years
    —
    5 Years
    +46%
    3 Years
    +62%
    TTM
    +96%

    Stock Price CAGR

    10 Years
    —
    5 Years
    +53%
    3 Years
    +95%
    1 Year
    +132%

    Return on Equity

    10 Years
    +20%
    5 Years
    +18%
    3 Years
    +18%
    Last Year
    +24%

    Strengths and risks are a machine-generated checklist, not advice; growth is compounded annually over each period.

    Shareholding pattern

    Percentage of shares held by each category at each quarter end
    HolderDec 2025Mar 2026Jun 2026Sept 2026Change
    Promoter32.66%32.66%32.66%32.66%0.00 pp
    FII16.67%19.48%21.61%22.61%+1.00 pp
    DII21.70%19.60%19.55%19.40%-0.15 pp
    Government0.01%0.01%0.01%0.01%0.00 pp
    Public28.96%28.24%26.16%25.31%-0.85 pp

    Filed with NSE for Sept 2026: promoters 32.66%, public 67.34%

    Risk & trend

    From 292 daily sessions to 18 Nov 2026.

    Computed

    Risk

    Volatility (1Y)
    45.4%
    Downside volatility
    42.4%
    Worst 5% of days
    4.1%
    Average of that tail
    5.7%
    Max drawdown (1Y)
    17.5%
    Below its peak
    1.2%

    Against the market

    Beta vs Nifty 50
    0.74
    Correlation
    0.22
    Relative strength (3M)
    +20.9%
    ATR (14)
    4.1%

    Return

    Return 1M
    +24.5%
    Return 3M
    +24.8%
    Return 6M
    +42.6%
    Return 1Y
    +126.2%
    vs 200-day average
    +35.2%

    Momentum

    RSI (14)
    65.1
    MACD histogram
    5.19
    Stochastic %K
    69.6
    ADX (14)
    29.3
    +DI / −DI
    26.2 / 13.4
    Money flow index
    72.6

    Participation

    Delivery (20d avg)
    44.7%
    vs its 60-day baseline
    -3.2 pts
    Volume vs 20-day
    -0.6σ
    Close vs day's VWAP
    +0.0%
    52-week position
    98 / 100

    These describe what this stock's price has already done. They are not forecasts, signals or recommendations, and a dash means the figure was withheld for want of enough history rather than being zero.

    Financial quality

    From consolidated statements to 30 Sept 2026.

    Computed

    Piotroski F-Score

    4 of 6 tested

    • Return on assets positive — passed
    • Operating cash flow positive — not testableno cash flow statement for this period
    • Return on assets improving — passed
    • Cash flow exceeds profit — not testableneeds cash flow and profit against assets
    • Debt to assets falling — failed
    • Current ratio improving — failed
    • No new equity issued — not testableno share count is collected, and financing cash flow mixes equity with debt
    • Operating margin improving — passed
    • Asset turnover improving — passed
    Free cash flow
    -₹36 Cr
    FCF yield
    -0.1%
    Cash conversion
    0.82
    Accruals ratio
    0.032
    Net debt
    -₹274 Cr
    Net debt / equity
    -0.15
    EV / sales
    20.35
    Capex intensity
    24.5%
    Revenue CAGR
    26.1%
    Profit CAGR
    56.7%

    Computed from filed statements, not filed themselves. A dash means an input was absent, and the score counts only the criteria that could actually be tested.

    Insider trades

    Last 12 months, market trades
    Net selling ₹4.0 Cr
    1 buys · ₹35.1 L
    2 sells · ₹4.3 Cr
    Latest insider trades disclosed to NSE
    PersonTypeSharesValueDisclosed
    Hemant Mahendabhai Patel
    Designated Person · Pledge Creation
    Pledge1,000₹32.7 L2 Oct 2026
    Vijay Gosar
    Employees/Designated Employees · Market Sale
    Sell500₹10.7 L10 Mar 2026
    MEHUL MANSUKHBHAI KOLADIA
    Employees/Designated Employees · Market Sale
    Sell20,000₹4.2 Cr20 Feb 2026
    Bhavesh Mansukhbhai Kotadiya
    Employees/Designated Employees · Market Purchase
    Buy2,100₹35.1 L30 Dec 2025

    Disclosures filed with NSE under SEBI (Prohibition of Insider Trading) Regulations. Pledges and releases are not trades and are not counted above.

    Corporate actions

    • dividend
      ₹2.50

      Dividend - Rs 2.50 Per Share

      17 Sept 2026
      ex-date
    • dividend
      ₹1.50

      Dividend - Rs 1.50 Per Share

      18 Sept 2025
      ex-date
    • split
      Not available — not reported in this filing

      Face Value Split (Sub-Division) - From Rs 10/- Per Share To Rs 5/- Per Share

      25 Apr 2025
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      13 Sept 2024
      ex-date
    • dividend
      ₹3.00

      Dividend - Rs 3 Per Share

      13 Sept 2024
      ex-date
    • dividend
      ₹3.00

      Dividend - Rs 3 Per Share

      18 Sept 2023
      ex-date
    • other
      Not available — not reported in this filing

      Annual General Meeting

      18 Sept 2023
      ex-date
    • dividend
      ₹3.00

      Annual General Meeting/Dividend - Rs 3 Per Share

      29 Jul 2022
      ex-date

    Company announcements

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Equirus Securities has organised an Earnings Conference Call on Tuesday, October 27, 2026 at 4.00 P.M. (IST) to discuss the financial results of the Company for the second quarter and half ....

    Board MeetingPrice-sensitive
    Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended September 30, 2026 Scheduled On October 27, 2026.

    Acutaas Chemicals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/10/2026 ,inter alia, to consider and approve Unaudited standalone & consolidated ....

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Updates on Acquisition

    Completion of the Acquisition of the shares of the Step-down Subsidiary - Enchem Ami Organics Private Limited as per details attached.

    Company Update
    Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended September 30, 2026 is attached.

    Company Update
    Announcement under Regulation 30 (LODR)-Change in Management

    Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 is enclosed.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Scrutinizer's Report

    Voting Results and Scrutinizers Report for the Annual General Meeting of the Company held on September 24, 2026 is attached.

    Company UpdatePrice-sensitive
    Announcement under Regulation 30 (LODR)-Acquisition

    Board of Directors have approved the acquisition of equity shares of step down subsidiary company as per details enclosed.

    AGM/EGMPrice-sensitive
    Shareholder Meeting / Postal Ballot-Outcome of AGM

    Disclosure of events of the 19th Annual General Meeting held on Thursday, September 24, 2026 is attached.

    Company Update
    Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    Intimation of Schedule of Investor Conference/Meet as per details attached.

    Insider Trading / SAST
    Closure of Trading Window

    Intimation of Closure of Trading Window is attached.

    Company Update
    Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Grant Of Patent

    Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 is attached.

    Company Update
    Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Inauguration Of New Pilot Plant

    Intimation under Regulation 30 of the SEBI (LODR) Regulations, 2015 in respect of inauguration of Pilot Plant today at Unit-1 Sachin is enclosed.

    Company Update
    Announcement under Regulation 30 (LODR)-Newspaper Publication

    Newspaper publication for dispatch of notice of 19th AGM along with Annual Report for the FY 2025-26 is enclosed.

    Company Update
    TDS Communication To Shareholders

    Communication to shareholders issued in respect of deduction of TDS on Dividend , is herewith enclosed.

    Corp. Action
    Intimation Of Record Date For The Purpose Of Final Dividend

    Intimation of Record date fixed for the purpose of Final Dividend for the FY 2025-26 is herewith enclosed.

    Filed with BSE (scrip 543349); the last 45 days. Documents open at bseindia.com.

    SEBI filings & orders

    From SEBI's website. An order may concern the company, its officers or trading in its shares, and may be under appeal - read the order itself. Personal identifiers are withheld.

    Regulatory orders

    • Order

      Exemption Order under Regulation 11 of SEBI (SAST) Regulations, 2011 in the matter of Acutaas Chemicals Limited - Patel and Vaghasia Family Trust

      1 Oct 2025
      Read on SEBI
    • Order

      Exemption Order under Regulation 11 of SEBI (SAST) Regulations, 2011 in the matter of Acutaas Chemicals Limited - Vaghasia Family Trust

      1 Oct 2025
      Read on SEBI

    Documents

    Documents open at BSE or the rating agency that issued them.

    Sourced from the company's NSE XBRL filing dated 28 Oct 2026 (unaudited). View the source filing. Figures are as filed and are not investment advice.

    FAQ

    Acutaas Chemicals: common questions

    Answered from the figures on this page.

    Acutaas Chemicals last traded at ₹3,991.30 (NSE, as of 18 Nov 2026). The last session moved it up 1.23%.

    Acutaas Chemicals is valued at about ₹32,677 crore (NSE, as of 18 Nov 2026).

    Acutaas Chemicals trades at a price-to-earnings ratio of 74.72 (NSE, as of 18 Nov 2026). The P/E compares the share price with earnings per share, so it is only comparable between companies in the same industry.

    Acutaas Chemicals has traded between ₹1,570.00 and ₹4,130.00 over the past 52 weeks, to 18 Nov 2026. It is currently 95% of the way up that range.

    Acutaas Chemicals (ACUTAAS) is classified under Pharma on this site's screener.